UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Lowers Position in Unum Group (NYSE:UNM)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC decreased its stake in Unum Group (NYSE:UNM - Free Report) by 2.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 661,999 shares of the financial services provider's stock after selling 16,950 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.36% of Unum Group worth $39,349,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in UNM. Wedge Capital Management L L P NC increased its stake in Unum Group by 8.0% in the second quarter. Wedge Capital Management L L P NC now owns 872,808 shares of the financial services provider's stock valued at $44,609,000 after acquiring an additional 64,661 shares during the last quarter. Cetera Advisors LLC bought a new position in shares of Unum Group during the 1st quarter valued at about $703,000. Van ECK Associates Corp purchased a new position in shares of Unum Group during the 2nd quarter valued at about $3,945,000. My Legacy Advisors LLC bought a new stake in Unum Group in the 2nd quarter worth approximately $473,000. Finally, CoreCap Advisors LLC purchased a new stake in Unum Group in the second quarter worth approximately $2,007,000. Hedge funds and other institutional investors own 86.57% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the stock. Wells Fargo & Company upped their price objective on shares of Unum Group from $69.00 to $71.00 and gave the company an "overweight" rating in a research note on Thursday, October 10th. Morgan Stanley boosted their price target on Unum Group from $62.00 to $64.00 and gave the company an "equal weight" rating in a report on Wednesday, October 30th. UBS Group raised shares of Unum Group to a "hold" rating in a research report on Wednesday, October 9th. JPMorgan Chase & Co. lowered their price target on shares of Unum Group from $65.00 to $63.00 and set an "overweight" rating for the company in a research report on Thursday, October 3rd. Finally, Bank of America upped their price objective on shares of Unum Group from $54.00 to $63.00 and gave the stock a "neutral" rating in a report on Thursday, October 10th. Four analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $67.73.

Insider Buying and Selling at Unum Group

In other Unum Group news, CEO Richard P. Mckenney sold 67,795 shares of the firm's stock in a transaction that occurred on Thursday, September 5th. The shares were sold at an average price of $54.98, for a total transaction of $3,727,369.10. Following the sale, the chief executive officer now owns 1,065,868 shares in the company, valued at approximately $58,601,422.64. This trade represents a 5.98 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Timothy Gerald Arnold sold 10,000 shares of the firm's stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $76.92, for a total transaction of $769,200.00. Following the sale, the executive vice president now owns 54,827 shares in the company, valued at $4,217,292.84. The trade was a 15.43 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 175,709 shares of company stock valued at $11,726,114. Insiders own 0.93% of the company's stock.

Unum Group Stock Performance

UNM traded down $0.48 during mid-day trading on Wednesday, reaching $75.56. 723,212 shares of the company traded hands, compared to its average volume of 1,250,021. The stock has a market capitalization of $13.80 billion, a P/E ratio of 8.23, a P/E/G ratio of 1.09 and a beta of 0.79. Unum Group has a 52-week low of $42.09 and a 52-week high of $77.63. The company has a quick ratio of 0.28, a current ratio of 0.28 and a debt-to-equity ratio of 0.32. The company's fifty day moving average price is $66.61 and its 200-day moving average price is $57.88.

Unum Group (NYSE:UNM - Get Free Report) last posted its earnings results on Tuesday, October 29th. The financial services provider reported $2.13 earnings per share for the quarter, beating analysts' consensus estimates of $2.10 by $0.03. The company had revenue of $3.22 billion for the quarter, compared to the consensus estimate of $3.26 billion. Unum Group had a return on equity of 15.21% and a net margin of 13.76%. Unum Group's revenue was up 4.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.94 earnings per share. On average, sell-side analysts expect that Unum Group will post 8.53 EPS for the current year.

Unum Group Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, November 15th. Investors of record on Friday, October 25th were given a dividend of $0.42 per share. The ex-dividend date was Friday, October 25th. This represents a $1.68 annualized dividend and a yield of 2.22%. Unum Group's dividend payout ratio (DPR) is 18.18%.

Unum Group Company Profile

Unum Group, together with its subsidiaries, provides financial protection benefit solutions primarily in the United States, the United Kingdom, Poland, and internationally. It operates through Unum US, Unum International, Colonial Life, and Closed Block segment. The company offers group long-term and short-term disability, group life, and accidental death and dismemberment products; supplemental and voluntary products, such as individual disability, voluntary benefits, and dental and vision products; and accident, sickness, disability, life, and cancer and critical illness products.